how does difference in medical practice in japan and the rest of the world effect drug development?...
TRANSCRIPT
How does difference in medical practice in Japan and the rest of the world effect drug development?
_ in the field of antidepressants _and antipsychotics
Mitsukuni Murasaki(Institute of CNS Pharmacology)
Antidepressants (1)
Use of placebo
in any stage PossibleUSA, CanadaScandinavian countries
three armsRecommended
European countries
Impossible Germany, Japan
randomized withdrawal study (relapse/recurrence)
Necessary Europe
Recommended
Japan
Antidepressants (2)
Bridging study - possible in Japan -・ same protocol・ same subject group・ same drug therapy
assessment of diagnostic criteriaDSM-ⅣICD-10
assessment of efficacy criteriaCGIHAM-DMADRS
Training for inter-rater reliability
Antidepressants (3)
Phase ⅠstudyPhase Ⅱa studyPhase Ⅱb studyPhase Ⅲ study two comparative trials
TCA trazodon → SSRI SNRI
Long-term study
Antipsychotics (1)
Use of placebo
Possible USA, Canada
ImpossibleEuropeJapan
Schizophrenia - Progressive and irreversible the earlier, the better
Antipsychotics (2)
Bridging study (1) -difficult in Japan-assessment of diagnostic criteria
DSM-ⅣICD-10 paranoid
disorganized (hebephrenic)
schizo - affectiveassessment of efficacy criteria
CGIBPRSPANSS
assessment of adverse eventsEPS DIEPS
Simpson – AngusAkathisia Barnes
Training for inter-rater reliability
Antipsychotics (3)
Bridging study (2)
protocol
subject groupacute/acute exacerbation USAchronic Japan
method for drug therapymono therapy USAcombination therapy
Japan
Antipsychotics (4)
Phase ⅠstudyPhase Ⅱa studyPhase Ⅱb studyPhase Ⅲ study two comparative trials in Japan
haloperidolmosapramine → atypicals
(risperidone)Long-term study